



DESIGN PROJECT FOR PRODUCTION OF IFN-ALPHA

IPRO 345 Chemical Engineering Design IPRO







- Design a process for production of the biotherapeutic compound IFN-Alpha from Chinese Hamster ovaries
- Assess whether the production design of this biotherapeutic compound is economically feasible and profitable





Background to Interferons

- Appear early after viral infection locally and systematically to limit spread of viral infection
- Inhibit viral activity by preventing RNA replication of the invading virus and certain other types of antigens and mark out tumor cells to be destroyed.
- Three naturally occurring forms: alpha, beta and gamma.





Background of Interferon-Alpha

- B-lymphocytes are the cellular producers of INF-alpha
- IFN-alpha is a multifunctional immunomodulatory cytokine
- IFN-alpha was approved by the Federal and Drug Administration (FDA) on February 25, 1991 to treat hepatitis C





Uses of Interferon-Alpha

- IFN-alpha remains the most frequently used IFN for both research and clinical applications
- Anti-viral applications such as chronic Hepatitis B and C now make up the bulk of IFN sales





Outline of IFN-alpha production







Cell Preparation

- Stimulation of T-cells by activator
- T-cells are collected and undergo RNA isolation
- Real Time RT-PCR to amplify the IFN-alpha gene
- PCR Amplification of IFN-alpha gene with restriction enzyme sites encoded on each end
- Cloning of the IFN-alpha insert into an appropriate cloning vector to verify correct PCR amplification





- IFN-alpha will be excised from the cloning vector and incorporated into the pSecTag2/Hygro vector to eventually allow for purification of Histidine-tagged proteins
- The IFN-alpha/pSecTag2/Hygro vector can be appropriately transfected into CHO cells to allow for the secretion of IFN-alpha
- A batch reactor system will be used for production





Histidine-tagged protein purification

- "His-tag" is the most commonly used tag for the facilitation of the purification of expressed recombinant proteins by affinity chromatography.
- A protein containing a histidine-tag is selectively seperated based on affinity to a metal-ion charged medium.





Nickel-affinity column

- A gravity flow purification system which allows for separation of histidine-tagged proteins.
- Histidine-tagged proteins will be bound to the resin based on their Ni²⁺ affinity once a binding buffer is passed through the column.
- An elution buffer can be used to separate only the successfully histidine-tagged IFN-alpha proteins.







Cells + Nutrients \rightarrow More cells + Products







Batch Reactor Cell Growth Equations

$$\frac{dC_{c}}{d} = \mathcal{F}_{g} - \mathcal{F}_{a} \qquad C_{c} = C_{c0}(e^{t}) \quad C_{c} = C_{c}e^{\left(\mathcal{F}_{d} \times \frac{C_{c}}{C_{c} + K_{s}}\right)}$$

Based on constraint of given variables and specified production output, two 1150 L batch reactors in parallel were designed

388 g of IFN-Alpha/cycle 30 cycles/year Production Rate : 10 kg/yr





Separation

Ni-Affinity Absorption Column



Resin attaches to IFN-Alpha and after water is removed buffer is added for detachment





Separation Stages

Centrifuge: Uses rotation around fixed axis so centrifugal force is used for separating materials based on densities

Ultra filtration : Uses pressure through a semi-permeable membrane with pores sized to retain solids and pass water

Freeze Drying: Removes water from the food matrix by sublimation and is useful for sensitive and high-valued fluids







GANTT CHART

A chart that depicts progress in relation to time, often used in planning and tracking a project.

G1= Growth	10								57			
C1=Clean)	Gantt Chart days										
S1=Separation 1												
		1	2	3	4	5	6	7	8	9	10	
G1		37/					20				10	
C1											10	
S1	1		1	<u> </u>		1	a de la companya de l Companya de la companya			1		





Cost Estimate

- Total bare module cost for fabricated equipment, CTFE: \$186,000.
- Total direct permanent Investment CDPI: \$416,600.
- Total Depreciable capital CTDC: \$561,100.
- Total permanent investment: \$639,700.



Approximate Profitability Analysis

- Minimum Proposed price of IFN-alpha: 1mg = 40 cents.
- Sales of 10kg of IFN-alpha: \$ 4million.
- Total production cost: \$ 3.5million.
- Pre-tax Earnings: \$463,000.
- Net Earnings: \$292,000.
- Process is Profitable.



Approximate Profitability Analysis

• 30 % return on Investment.

Payback Period: 1.667yr

Process is still profitable at subsidized price.





Rigorous Profitability Analysis

- Investor's return rate: 23.76%.
- Emphasizes profitability.



Discounted Annual Cash Flow Over 15 yrs





Humanitarian Consideration

- High Price of product is a deterrent to patients.
- A lot of people need this product.
- Give out certain amount of free products.
- Sell at subsidized price.
- Suggested Selling price: 1mg = 40 cents.





Conclusion

- Large scale production of IFN-alpha would increase supply to meet its demand.
- Positive effects on patients.
- More Competitive industry.
- Reduce high price of product.





Questions For more information, visit our website: www.iit.edu/~ipro345s06

ipro 345	Process Design and Economics of a Modern Bi describe the Marketability of the Product.	oengineered	Facility to p	roduce a Us	eful Product	ILLI based on Bi	INOIS INSTI OF TEC otechnology	TUTE CHNOLOGY and to
		Home	Project	Solution	Progress	Team	Links	Contact
IPRO 345 Home IPRO Home IIT Home	IPRO 345 Home Welcome to Ipro 345's home page for spring 2006. The projectrepresents continuing pioneering work in proteins. The protein is Interferon alpha (IFN-alpha)	n bioengineeri I.	ng process des	ign for engine	eering studen t	s in the produ	iction of bio-th	erapeutic
Search vvvv vvv vvv vvv vvv vvv vvvv vvvvv vvvvv vvvv vvvv vvvv vvvv vvvv vv		Theoretical s	etructure of it	nterferon al	bha			